Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
Currently predicting for Fri, 10 May 2024

Trading levels for NTLA

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 25.97 4.48 %
R2 25.37 2.04 %
R1 24.99 0.526 %
Current price: 24.86
Support S1 23.78 -4.36 %
S2 23.40 -5.87 %
S3 22.79 -8.31 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 31.02 24.78 %
R2 28.47 14.52 %
R1 26.45 6.40 %
Current price 24.86
Support S1 22.92 -7.80%
S2 22.50 -9.49%
S3 20.02 -19.47%

NTLA Predictions History

2 years ago
JS predicted that NTLA for 2021-07-06 is going $162.28 (-0.87%)

2 years ago
email.lewandowski predicted that NTLA for 2021-07-06 is going

Rank:

3 years ago
JS predicted that NTLA for 2021-03-16 is going $66.81 (1.92%)

3 years ago
Candy2502 predicted that NTLA for 2021-03-16 is going $68.06 (3.83%)

Rank:

3 years ago
JS predicted that NTLA for 2021-01-12 is going $70.12 (-7.36%)

3 years ago
FabrizioSabatini predicted that NTLA for 2021-01-12 is going

Rank:

3 years ago
JS predicted that NTLA for 2020-06-04 is going $21.54 (4.36%)

3 years ago
Babylon predicted that NTLA for 2020-06-04 is going

Rank:

3 years ago
Matt Miller predicted that NTLA for 2020-06-04 is going $20.76 (0.58%)

Rank:

3 years ago
Mr. Glenn predicted that NTLA for 2020-05-12 is going $15.59 (-1.89%)

Rank:
Click to get the best stock tips daily for free!

About Intellia Therapeutics Inc

Intellia Therapeutics Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline... NTLA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT